Effect of different dosage combinations of nalbuphine and sufentanil on postoperative analgesia in patients undergoing abdominal hysterectomy surgeries

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900020599

Enrollment

Unknown

Registered

2019-01-09

Start date

2019-01-15

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after abdominal hysterectomy

Interventions

group S:The test drug is sufentanil 100ug

group NS1:The test drugs are sufentanil 75ug + nalbuphine 25mg

group NS2:The test drugs are sufentanil 50ug + nalbuphine 50mg

group NS3:The test drugs are sufentanil 25ug + nalbuphine 75mg

group N:The test drug is nalbuphine 100mg

Eligibility

Sex/Gender

Female

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Elective abdominal hysterectomy surgery patients; 2. Aged 30-60 years old, body mass index 18.5-30 kg/m2; 3. ASA I or II.

Exclusion criteria

Exclusion criteria: 1. Pregnancy and age and breast-feeding patients; 2. Patients with severe liver, kidney and cardiopulmonary diseases; 3. Patients with a history of mental illness; 4. Patients taking opioids for a long time; 5. History of allergic reactions to opioids; 6. patients with coagulopathy.

Design outcomes

Primary

Measure	Time frame
scores of incision pain of NRS;scores of visceral pain of NRS;Ramasy sedation scores;	—

Secondary

Measure	Time frame
number of analgesia pump compressions;	—

Countries

China

Contacts

Public ContactWang Jun

Xuzhou Medical University

wangjunmz@163.com+86 15298668999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026